Gleason Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Gleason Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.36K	Hold	16	–	–	﹤0.01%	234
2026 Q2	$7.95K	Buy	+16	New	+$7.09K	﹤0.01%	250

Other funds holding VRTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Gleason Group's VRTX Position: Q3 2026 in Review

Gleason Group held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 16 shares worth $8.36K. The position accounts for ﹤0.01% of the portfolio, ranked #234.

Gleason Group first reported a position in VRTX in Q2 2026 and has held it in 2 quarters since. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Gleason Group held 16 shares of Vertex Pharmaceuticals worth $8.36K as of Q3 2026.
Gleason Group left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Gleason Group's portfolio in Q3 2026, its #234 holding.
Gleason Group first reported a position in Vertex Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Gleason Group's 13F filing for Q3 2026, filed 15 Oct 2026.